Biotech IV Monitor

NUVB — Nuvation Bio Inc. Class A

$2.2B market cap · 0 upcoming readouts tracked

Clinical trial readout dates for Nuvation Bio Inc. Class A, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced.

Market cap$2.2B
Cash & investments$663M~16 quarters at last loss rate
Recent 8-K filings1latest 2026-11-04

In progress, no date published

Phase 3 Safusidenib
Grade 2 IDH1-mutant glioma
date not published
Trial Planned
Phase 2 Safusidenib with vorasidenib
IDH1-mutant glioma
date not published
Trial Planned

Cash position

Nuvation Bio Inc. Class A reported $663M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). Its net loss for that quarter was $42M; at that rate the cash would last about 16 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-04

Companies working on similar indications

Discussion

No messages yet. If you follow NUVB, you can start the conversation.
Track NUVB in real time
See live implied volatility for NUVB and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on NUVB
Contact — questions or corrections about NUVB: dukeupt@gmail.com